Simris Alg AB Class B (SIMRIS.B) AI Stock Analysis

• Market Cap: kr117.43M
• Dividend Yield: N/A
• Average Volume (3M): 223.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: -49.72%
• EPS Growth: 36.20%
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,349,793,200
• 10 Day Avg. Volume: 120,731
• 30 Day Avg. Volume: 223,875
• PEG Ratio: 0.02
• Price to Book (P/B): 4.70
• Price to Sales (P/S): 9.18
• P/FCF Ratio: -1.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: kr0.13 ▲(215.00% Upside)
• Action: Downgraded Date: 02/04/26
• Date: Action: Downgraded 02/04/26

The score is primarily held down by poor financial performance—declining revenue, extremely negative margins, ongoing cash burn, and a weak equity position. Technicals show recent upward momentum but with overbought conditions, while valuation remains unattractive due to losses and no dividend support.

Positive Factors

Algae-based omega-3 product niche

Simris operates in a structural growth niche supplying algae-derived omega-3 oils, a sustainable alternative to fish oil. Vertical activities from cultivation to commercialization support control over quality and supply, giving a durable product differentiation aligned with plant-based and sustainability trends.

Healthy product-level gross margin

A 42.11% gross margin indicates the core product has favorable unit economics, implying the business can be profitable at scale if fixed costs and operating expenses are controlled. This margin durability supports a feasible pathway to profitability with revenue recovery or scale.

Low reported financial leverage

No reported debt reduces interest burden and bankruptcy risk, providing financial flexibility to pursue additional financing, partnerships, or R&D without immediate debt-servicing pressure. This structural balance-sheet attribute aids resilience during revenue recovery phases.

Negative Factors

Declining revenue and extreme losses

Steep revenue contraction coupled with an extremely negative EBIT margin signals the company cannot cover fixed costs and is failing to commercialize volumes. These are structural operating weaknesses that, unless reversed by sustained sales growth or cost restructuring, threaten long-term viability.

Persistent cash burn; financing dependence

Ongoing negative operating cash flow with positive financing inflows shows operations are not self-funding and rely on external capital. Continued dependence on fundraising risks dilution and funding gaps; sustainable value creation requires consistent positive cash generation, which is currently absent.

Very weak equity and solvency cushion

An extremely low equity ratio and small absolute equity base leave little buffer to absorb further losses, constrain borrowing capacity and supplier confidence, and increase solvency risk. This structural weakness limits the firm's ability to scale or withstand prolonged operational stress.

Simris Alg AB Class B Business Overview & Revenue Model

Company Description

Simris Alg AB Class B (SIMRIS.B) is a Swedish biotechnology company focused on the sustainable production of high-value products derived from microalgae. Operating primarily in the sectors of food, health, and nutrition, Simris Alg specializes in cultivating various species of algae to create ingredients such as omega-3 fatty acids, proteins, and other bioactive compounds. The company aims to provide natural alternatives to commercially available products, promoting health and wellness while minimizing environmental impact.

How the Company Makes Money

Simris Alg generates revenue primarily through the sale of its algae-derived products, which include omega-3 supplements and other nutritional ingredients. The company has developed a range of branded products aimed at both consumers and health-focused businesses. Key revenue streams include direct sales to consumers via e-commerce platforms, partnerships with health and wellness retailers, and collaborations with food and supplement manufacturers seeking natural ingredients. Additionally, strategic partnerships with research institutions and collaborations with other companies in the biotechnology space enhance its R&D capabilities and market reach, contributing positively to its financial performance.

Simris Alg AB Class B Financial Statement Overview

Summary

Weak fundamentals: revenue declined (SEK 4.35M in 2023 to SEK 2.89M in 2024), profitability is severely negative (2024 EBIT margin -1201%), and cash flow remains negative (operating cash flow SEK -18.02M; negative free cash flow). The balance sheet also looks fragile with very low equity and a sharply reduced equity ratio (3.59%), raising solvency concerns.

Income Statement

Simris Alg AB Class B has faced declining revenues, evident from a revenue drop from SEK 4.35M in 2023 to SEK 2.89M in 2024. Consistent negative EBIT and EBITDA margins highlight operational inefficiencies, with the EBIT margin at -1201% for 2024. Despite a gross profit margin of 42.11% in 2024, the net profit margin remains deeply negative, reflecting significant net losses. These factors indicate substantial challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a highly leveraged position with a debt-to-equity ratio at zero due to no reported debt, but low equity levels of SEK 5.64M. The equity ratio has drastically decreased to 3.59% in 2024, suggesting potential solvency issues. The return on equity is negative due to persistent net losses, which raises concerns about shareholder value.

Cash Flow

Operating cash flow improved compared to the prior year, though still negative at SEK -18.02M in 2024, indicating ongoing cash burn. The free cash flow remains negative, suggesting unsustainable operations without external financing. Despite this, financing cash flow at SEK 14.91M shows efforts to secure additional funding. The free cash flow to net income ratio remains negative, reflecting challenges in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.58M	2.89M	4.35M	4.08M	6.14M	2.17M
Gross Profit	1.80M	1.22M	2.01M	-742.00K	-2.07M	-2.75M
EBITDA	-12.86M	-17.59M	-22.36M	-18.00M	-24.81M	-20.66M
Net Income	-29.35M	-34.60M	-37.30M	-24.42M	-28.36M	-25.60M
Balance Sheet
Total Assets	144.79M	157.06M	174.55M	185.71M	29.20M	57.06M
Cash, Cash Equivalents and Short-Term Investments	1.03M	1.95M	5.67M	3.99M	961.00K	16.51M
Total Debt	90.78M	2.04M	2.67M	2.13M	3.13M	3.99M
Total Liabilities	152.53M	151.42M	148.94M	162.68M	10.98M	9.64M
Stockholders Equity	-7.75M	5.64M	25.61M	23.03M	18.22M	47.42M
Cash Flow
Free Cash Flow	-13.32M	-18.63M	-37.96M	-40.57M	-18.39M	-19.77M
Operating Cash Flow	-13.32M	-18.02M	-36.35M	-18.19M	-18.14M	-19.48M
Investing Cash Flow	-613.00K	-613.00K	-1.61M	-22.38M	-253.00K	-286.00K
Financing Cash Flow	13.22M	14.91M	39.63M	43.60M	2.84M	28.42M

Simris Alg AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.08, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.63 is Neutral, neither overbought nor oversold. The STOCH value of 22.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SIMRIS.B.

Simris Alg AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EXPRS2	45 Neutral	kr54.01M	-1.12	-88.65%	―	8.46%	11.73%
PILA	44 Neutral	kr48.31M	-2.39	-601.02%	―	―	―
MODTX	43 Neutral	kr37.83M	-1.33	-166.94%	―	―	-19.35%
ONCOZ	41 Neutral	kr71.96M	-9.09	-78.79%	―	―	20.55%
LPGO	41 Neutral	kr2.79M	-0.08	-213.85%	―	―	―
SIMRIS.B	40 Underperform	kr117.43M	-1.25	―	―	-49.72%	36.20%